ImmunityBio's ANKTIVA gains UK approval for bladder cancer treatment, positive.

ImmunityBio Inc. has received marketing authorization from the UK MHRA for ANKTIVA in combination with BCG for certain bladder cancer patients. ANKTIVA was designated a Breakthrough Therapy by the FDA and has shown positive outcomes in complete response and duration of response. The company is also seeking regulatory approval in the EU. This marks the first marketing approval outside the U.S. for this lymphocyte-stimulating agent. For more health news, visit rttnews.com. Note: Views expressed are the author’s and not necessarily Nasdaq, Inc.’s.

Read more at Nasdaq: ImmunityBio’s ANKTIVA Gains UK Approval In Bladder Cancer Treatment